OPINION:
President Trump announced this month that TrumpRx will expand its discounted prescription drug platform nearly sevenfold by adding more than 600 generic medications. It marks one of the administration’s biggest healthcare affordability moves yet.
The president knows all too well that the current healthcare system forces Americans to pay more for prescription drugs as insurance companies and pharmacy benefit managers (PBMs) jack up costs.
These companies often pocket pricing discounts for themselves, while nearly one in three Americans can’t afford to pay for medications prescribed to them by a doctor.
TrumpRx and other direct-to-consumer (DTC) prescription platforms like Cost Plus Drugs and LillyDirect help direct consumers toward lower-cost options that come directly from the drug manufacturers themselves instead of through PBMs, pass-through companies that mark up the costs of life-saving medications, and insurers, which add an extra layer of bureaucracy.
These DTC platforms don’t manufacture or dispense medications. Instead, they function as price-comparison platforms that show consumers the cheapest available pharmacy or direct-purchase option nationwide.
TrumpRx.gov essentially does for prescription drugs what travel sites did for airline tickets and hotels. Before travel websites, consumers often had little visibility into price differences between sellers. Websites like Expedia and Hotwire.com changed that, and TrumpRx is applying their same transparency model to prescription drugs.
This forces more price competition, which in turn lowers costs for patients.
Patients can use TrumpRx to locate the lowest-priced pharmacy in their neighborhood. And if they want a better option, they can order discount prescriptions online and receive them at their homes in two days or less.
This makes it increasingly difficult for the insurers to raise the cost of medications. With TrumpRx exposing competing prices across the country and allowing patients to shop around, insurers can no longer hold consumers captive inside opaque pricing systems.
Even at this early juncture, there are too many success stories to count.
When it comes to weight loss, Americans can use TrumpRx to purchase Wegovy for $149, a fraction of the original listing price. Humira, which treats rheumatoid arthritis, was reduced from $7,000 to $950. That drug lost its patent protection in 2023, but generic equivalents are available on TrumpRx for almost $208 a dose.
Genentech will sell its flu treatment Xofluza for about $50, down from $168.
In vitro fertilization treatments are prohibitively expensive but not covered by insurance. TrumpRx offers a nearly 85% discount on a trio of IVF drugs.
As for diabetes, officials with Merck and Sanofi recently got on board with TrumpRx. Merck added three medications (Januvia, Janumet and Janumet XR) and cut costs by 74%.
In some cases, the discounted generics available through direct-to-consumer platforms like TrumpRx are offered at an even lower cash price than the out-of-pocket insurance cost.
Healthcare affordability remains one of the biggest financial pressures facing working- and middle-class Americans. DTC pharmaceuticals are a market-based way to lower high drug prices without expanding government-run healthcare or imposing broad price controls that backfire in other ways.
The DTC model is proving that there are viable market-based solutions to one of patients’ most pressing public policy concerns.
When patients can see real prices, compare options and buy medicine without unnecessary middlemen, competition starts working again. DTC tools like TrumpRx facilitate a prescription drug market where patients know what they are paying, have more than one place to buy and are no longer forced to navigate a system designed to hide prices rather than lower them simply by bringing purchasing decisions directly to patients.
• Justin Leventhal is a senior policy analyst for the American Consumer Institute, a nonprofit education and research organization that advocates for consumers through evidence-based analysis and data. Follow Justin on X @JustinLeventhal.
Please read our comment policy before commenting.